Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma

Clinical Lung Cancer

Volumn 14, Issue 3, 2013, Pages 238-244

  Sulpher, Jeffrey A ^a   Owen, Scott P ^b   Hon, Henrique ^b   Tobros, Kimberly ^b   Shepherd, Frances A ^b   Sabri, Elham ^c   Gomes, Marcio ^d   Sekhon, Harman ^d   Liu, Geoffrey ^b   Canil, Christina M ^a   Wheatley Price, Paul ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Chart review; Diagnosis; Histology; Non small cell lung cancer

Indexed keywords

AGED; ARTICLE; BRONCHOSCOPY; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; MULTICENTER STUDY; TERTIARY HEALTH CARE;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 84879895777     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.11.004     Document Type: Article

References (30)

1. A. Jemal, F. Bray, M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. R. Siegel, E. Ward, O. Brawley Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2011 212 236
3. Canadian Cancer Society's Steering Committee on Cancer Statistics Canadian Cancer Statistics 2011 2011 Canadian Cancer Society Toronto, ON http://www.ncic.cancer.ca Accessed: December 20, 2012
4. American Cancer Society Cancer Facts and Figures 2011 2011 American Cancer Society Atlanta, GA
5. T. Itaya, N. Yamaoto, M. Ando Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer Cancer Sci 98 2007 226 230
6. M.J. Thun, C.A. Lally, J.T. Flannery Cigarette smoking and changes in the histopathology of lung cancer J Natl Cancer Inst 89 1997 1580 1586
7. W.D. Travis, E. Brambilla, M. Noguchi International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
8. L.H. Einhorn First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 26 2008 3485 3486
9. F.R. Hirsch, A. Spreafico, S. Novello The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review J Thorac Oncol 3 2008 1468 1481
10. G. Scagliotti, N. Hanna, F. Fossella The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 2009 253 263
11. G. D'Addario, M. Früh, M. Reck Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 2010 S116 S119
12. P.M. Ellis, N. Blais, D. Soulieres A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer J Thorac Oncol 6 2011 1379 1391
13. G.V. Scagliotti, P. Parikh, J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
14. P. Ceppi, M. Volante, S. Novello ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine Ann Oncol 17 2006 1818 1825
15. T. Nakagawa, Y. Otake, K. Yanagihara Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC) Lung Cancer 43 2004 145 149
16. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
17. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
18. J.G. Paez, P.A. Jänne, J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
19. W. Pao, V. Miller, M. Zakowski EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311
20. D.H. Johnson, L. Fehrenbacher, W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
21. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
22. E.L. Kwak, Y.J. Bang, R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
23. F.L. Greene, D.L. Page, I.D. Fleming et al. American Joint Committee on Cancer Cancer Staging Manual 6th ed. 2002 Springer-Verlag New York, NY
24. J.E. Grilley-Olsen, D.N. Hayes, B.F. Qaqish Diagnostic reproducibility of squamous cell carcinoma (SCC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: a large prospective study J Clin Oncol 27 suppl 15 2009 8008
25. C.R. Payne, J.W. Hadfield, P.G. Stovin Diagnostic accuracy of cytology and biopsy in primary bronchial carcinoma J Clin Pathol 34 1981 773 778
26. L. Sakr, P. Roll, M.J. Payan Cytology-based treatment decision in primary lung cancer: is it accurate enough? Lung Cancer 75 2012 293 299
27. D.L. Aisner, C. Deshpande, Z. Baloch Evaluation of EGFR mutation status in cytology specimens: an institutional experience Diagn Cytopathol 2011 [Epub ahead of print]
28. H. Sekhon, M. Gomes, C. Souza Are cytology samples optimal for EGFR mutation analysis for medical oncology clinics and do they measure up? Virchows Arch 456 suppl 1 2011 S134
29. R. Ocque, N. Tochigi, N.P. Ohori Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens Am J Clin Pathol 136 2011 81 87
30. N. Rekhtman, D.C. Ang, C.S. Sima Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens Mod Pathol 24 2011 1348 1359